

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. PU60789	INTERNATIONAL APPLICATION NO. PCT/US2004/008032
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Busch-Petersen et al.	
		FILING DATE Herewith Sept. 14, 2006	GROUP 1624

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
/B.C./		U.S. 6,605,607 B1	12-Aug- 2003	HADLEY et al.	514	217.01	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/B.C./	AUSTIN et al., Novel 2,3,4,5-Tetrahydro-1H-3-benzazepinweisth High Affinity and Selectivity for the Dopamine D _{sub.3} Receptor, Bioorganic & Medicinal Chemistry Letters, 20 November 2000, Vol. 10, No. 22, pages 2553-2555, especially pages 2554 and 2555.
/B.C./	MACDONALD et al., Design and Synthesis of trans-3-(244-((3-(3-(5-Methyl-1,2,4-oxadiazolyl)-phenyl)carbomido)cyclohexyl)ethyl)-7-mylsfonyl-2,3,4,5-tetrahydrolH-3-benzazepine (SB-414796): A Potent and Selective Dopamine D _{sub.3} Receptor Antagonist, Journal of Medicinal Chemistry, 06 November 2003, Vol. 46, No. 23, pages 4952-4964, especially pages 4956 and 4957.
EXAMINER	/Brenda Coleman/
	DATE CONSIDERED 09/28/2008

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.